Aquestive Therapeutics, Inc. (AQST) Gross margin 2019–2025
Aquestive Therapeutics, Inc. (AQST) gross margin by fiscal year — reported gross profit divided by reported revenue.
58.3%FY2025 · since FY2019: 61.3% → 58.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 58.3% | -10.6 pp |
| FY2024 | 69.0% | +10.1 pp |
| FY2023 | 58.8% | -0.5 pp |
| FY2022 | 59.3% | — |
| FY2020 | 71.7% | +10.4 pp |
| FY2019 | 61.3% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Operating incomeAQST Operating marginAQST Operating cash flowAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →